Huntsman Cancer Institute at the University of Utah | Strategic Alliance Partners

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses his preferred frontline treatment for patients with kidney cancer.

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses the advantages and disadvantages of choosing docetaxel as a therapy for patients with mCRPC.

Neeraj Agarwal, MD, recaps the latest advancements in newly diagnosed RCC.

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses remaining questions in renal cell carcinoma.

A new study has provided yet more evidence that survivors of endometrial cancer should be closely monitored for cardiovascular disease.

Robert Andtbacka, MD, discusses how the role of oncolytic immunotherapies continues to evolve in melanoma and gives a better understanding of what is on the horizon for the novel therapeutics.

Due to the unique characteristics of adolescents and young adults, there is a growing effort to address their oncology needs.

Although CLL is the most common chronic leukemia, there remains no single agreed-upon standard of care for first-line treatment.

Jonathan Tward, MD, PhD, Associate Professor of Radiation Oncology at the Huntsman Cancer Institute, discusses abbreviated course androgen-deprivation therapy (ADT) for prostate cancer treatment.

Does renal disease increase one's risk of developing cancer?

Robert H. I. Andtbacka, MD, CM, from Intermountain Healthcare and Huntsman Cancer Institute, discusses the safety and efficacy of T-VEC in combination with ipilimumab in patients with previously untreated, unresected stage IIIB-IV melanoma.

There are few controversies in oncology as divisive as the value of prostate-specific antigen (PSA) screening and subsequent treatment for prostate cancer.

In the current digital age, where all-too-personal information flows from Facebook and Twitter, it seems that the health information available through the process of genetic testing would be an idea welcomed by most of the public.

T-VEC manifested significant gains in durable response rate and other key clinical indicators in patients with advanced melanoma in what researchers described as the first phase III trial demonstrating the efficacy of an oncolytic virus immunotherapy.